Research ArticleLumbar Spine

Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population

GREGORY S. COOPER and TZUYUNG DOUG KOU
International Journal of Spine Surgery April 2018, 12 (2) 260-268; DOI: https://doi.org/10.14444/50323

Article Figures & Data

Figures

  • Figure
    Figure

    Kaplan-Meier plot of malignant neoplasia risk in recombinant human bone morphogenic protein (rhBMP)-treated and untreated patients. Through a follow-up period of up to 8 years, patients receiving rhBMP were at similar risk to receive a cancer diagnosis as untreated patients (P = .2687 by log-rank test).

Tables

  • Table 1
  • Table 2
  • Table 3
  • Appendix
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population
GREGORY S. COOPER, TZUYUNG DOUG KOU
International Journal of Spine Surgery Apr 2018, 12 (2) 260-268; DOI: 10.14444/50323
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords